Heidelberg

• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting
  2022-501007-28-00 5 2023-04-18 Breast Neoplasms
• OLE study in participants with pulmonary arterial hypertension Recruiting
  2023-505539-11-00 10 2023-04-06 Pulmonary Arterial Hypertension
• A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K in … Recruiting
  2022-501152-28-00 4 2022-12-21 Breast Cancer
• Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting
  2022-502503-30-00 5 2022-12-15 Acute lymphoblastic leukemia
• A Study of Abemaciclib (LY2835219) with Abiraterone in Men with Prostate Cancer that has Spread to Other Parts of the Body and is Expected t … Recruiting
  2022-500461-28-06 5 2022-09-15 High-Risk Metastatic Hormone-Sensitive Prostate Cancer
• Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose … Recruiting
  2024-516066-11-00 5 2022-08-31 Patients with newly diagnosed, histologically confirmed, primary advan
• Phase 3 Trial of TAK-330 for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation Recruiting
  2022-503012-16-00 5 2022-07-20 Patients on treatment with Factor Xa Inhibitor needing for an urgent i
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan … Recruiting
  2023-505749-14-00 5 2022-03-20 c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
• A Long-term Follow-up Study of Sotatercept for PAH Treatment Recruiting
  2023-509138-21-00 5 2021-08-26 Pulmonary Arterial Hypertension (PAH)
• Study of efficacy and safety of iptacopan in complement 3 glomerulopathy patients Recruiting
  2023-509331-83-00 5 2021-07-28 complement 3 glomerulopathy
• A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS T … Recruiting
  2023-504084-17-00 9 2021-07-12 ALK fusion-positive extracranial solid or primary CNS tumors who have
• Evaluation of Conversion from Calcineurin Inhibitor- to Belatacept-based Immunosuppression in Adolescent Renal Transplant Recipients and the … Recruiting
  2022-501677-39-00 5 2021-05-25 Adolescent Renal Allografts
• Study for patients with Primary Hyperoxaluria and Severe Renal Impairment to evaluate the efficacy, safety and tolerability of DCR-PHXC. Recruiting
  2024-512259-19-00 4 2021-04-08 Primary Hyperoxaluria
• LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib in RET fusion-Positive NSCLC Recruiting
  2023-506784-33-00 5 2021-01-19 RET fusion-Positive NSCLC
• A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis Recruiting
  2023-506471-10-00 5 2019-10-04 Secondary hyperparathyroidism (SHPT) in pediatric patients with chroni
• A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) Recruiting
  2024-512358-78-00 7 2015-01-20 Solid Tumors
• ALL SCTped 2012 FORUM - Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia Recruiting
  2024-512657-24-00 10 2014-03-27 Acute Lymphoblastic Leukaemia
• NeoMatryx - Neoadjuvant Merkel cell carcinoma therapy (Tx) with the PD-1 inhibitor Cemiplimab – A randomized, double-blind, placebo-controll … Recruiting
  2025-522091-84-00 4 2026-05-29 Merkel Cell Carcinoma
• A clinical trial of MK-1084, pembrolizumab, and chemotherapy in people with nonsmall cell lung cancer (MK-1084-013) Recruiting
  2024-517337-41-00 5 2026-05-12 Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC
• A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-034) Recruiting
  2024-516993-31-00 5 2026-05-11 Renal Cell Carcinoma
• Dose Ranging Study of ORKA-001 in Patients with Moderate-to-Severe Plaque Psoriasis (EVERLAST-B) Recruiting
  2025-523797-17-00 4 2026-05-08 Moderate-to-Severe Plaque Psoriasis
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus E … Recruiting
  2025-523552-31-00 5 2026-05-07 Systemic Lupus Erythematosus
• Evaluating the clinical effectiveness of sodium bicarbonate for critically ill patients with metabolic acidosis and acute kidney injury Recruiting
  2025-523914-10-00 6 2026-04-30 Critical illness
• A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa Recruiting
  2025-522440-41-00 4 2026-04-27 Hidradenitis Suppurativa

Showing 97–120 of 732 trials